When endometrial cancer metastasizes, are the mets always the same genetic makeup of the original tumor or is there a possibility of further mutations? In other words, if my original tumor has had genomic testing through an organization like Foundation One, how can I be sure that the mets that have spread to my lungs have the same abnormalities and, therefore, might benefit from an immunotherapy suggested by the genomic testing of the original tumor?

Jump to this post